Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Identification of novel BRCA1 large genomic rearrangements by a computational algorithm of amplicon-based Next-Generation Sequencing data

View through CrossRef
Background Genetic testing for BRCA1/2 germline mutations in hereditary breast/ovarian cancer patients requires screening for single nucleotide variants, small insertions/deletions and large genomic rearrangements (LGRs). These studies have long been run by Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA). The recent introduction of next-generation sequencing (NGS) platforms dramatically improved the speed and the efficiency of DNA testing for nucleotide variants, while the possibility to correctly detect LGRs by this mean is still debated. The purpose of this study was to establish whether and to which extent the development of an analytical algorithm could help us translating NGS sequencing via an Ion Torrent PGM platform into a tool suitable to identify LGRs in hereditary breast-ovarian cancer patients. Methods We first used NGS data of a group of three patients (training set), previously screened in our laboratory by conventional methods, to develop an algorithm for the calculation of the dosage quotient (DQ) to be compared with the Ion Reporter (IR) analysis. Then, we tested the optimized pipeline with a consecutive cohort of 85 uncharacterized probands (validation set) also subjected to MLPA analysis. Characterization of the breakpoints of three novel BRCA1 LGRs was obtained via long-range PCR and direct sequencing of the DNA products. Results In our cohort, the newly defined DQ-based algorithm detected 3/3 BRCA1 LGRs, demonstrating 100% sensitivity and 100% negative predictive value (NPV) (95% CI [87.6–99.9]) compared to 2/3 cases detected by IR (66.7% sensitivity and 98.2% NPV (95% CI [85.6–99.9])). Interestingly, DQ and IR shared 12 positive results, but exons deletion calls matched only in five cases, two of which confirmed by MLPA. The breakpoints of the 3 novel BRCA1 deletions, involving exons 16–17, 21–22 and 20, have been characterized. Conclusions Our study defined a DQ-based algorithm to identify BRCA1 LGRs using NGS data. Whether confirmed on larger data sets, this tool could guide the selection of samples to be subjected to MLPA analysis, leading to significant savings in time and money.
Title: Identification of novel BRCA1 large genomic rearrangements by a computational algorithm of amplicon-based Next-Generation Sequencing data
Description:
Background Genetic testing for BRCA1/2 germline mutations in hereditary breast/ovarian cancer patients requires screening for single nucleotide variants, small insertions/deletions and large genomic rearrangements (LGRs).
These studies have long been run by Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA).
The recent introduction of next-generation sequencing (NGS) platforms dramatically improved the speed and the efficiency of DNA testing for nucleotide variants, while the possibility to correctly detect LGRs by this mean is still debated.
The purpose of this study was to establish whether and to which extent the development of an analytical algorithm could help us translating NGS sequencing via an Ion Torrent PGM platform into a tool suitable to identify LGRs in hereditary breast-ovarian cancer patients.
Methods We first used NGS data of a group of three patients (training set), previously screened in our laboratory by conventional methods, to develop an algorithm for the calculation of the dosage quotient (DQ) to be compared with the Ion Reporter (IR) analysis.
Then, we tested the optimized pipeline with a consecutive cohort of 85 uncharacterized probands (validation set) also subjected to MLPA analysis.
Characterization of the breakpoints of three novel BRCA1 LGRs was obtained via long-range PCR and direct sequencing of the DNA products.
Results In our cohort, the newly defined DQ-based algorithm detected 3/3 BRCA1 LGRs, demonstrating 100% sensitivity and 100% negative predictive value (NPV) (95% CI [87.
6–99.
9]) compared to 2/3 cases detected by IR (66.
7% sensitivity and 98.
2% NPV (95% CI [85.
6–99.
9])).
Interestingly, DQ and IR shared 12 positive results, but exons deletion calls matched only in five cases, two of which confirmed by MLPA.
The breakpoints of the 3 novel BRCA1 deletions, involving exons 16–17, 21–22 and 20, have been characterized.
Conclusions Our study defined a DQ-based algorithm to identify BRCA1 LGRs using NGS data.
Whether confirmed on larger data sets, this tool could guide the selection of samples to be subjected to MLPA analysis, leading to significant savings in time and money.

Related Results

Abstract 1563: Damage-induced BRCA1 phosphorylation contributes to the timing of end resection
Abstract 1563: Damage-induced BRCA1 phosphorylation contributes to the timing of end resection
Abstract Germline mutations of BRCA1 predispose women to breast and ovarian cancers. BRCA1 functions as a tumor suppressor. A wealth of evidence has established that...
Abstract 1716: Evaluating the functional impacts of the BRCA1-mTORC2 interaction in breast cancer
Abstract 1716: Evaluating the functional impacts of the BRCA1-mTORC2 interaction in breast cancer
Abstract Objective: The BRCA1 C-Terminal (BRCT) domain of BRCA1 has been found to interact with three accessory proteins (PRR5, RICTOR, and SIN1) of mTOR complex ...
Abstract 2595: Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Algerian breast/ovarian cancer families
Abstract 2595: Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Algerian breast/ovarian cancer families
Abstract Background: Breast cancer is the leading cause of cancer death in women in Algeria. To date, few molecular genetics studies of BRCA1 and BRCA2 germline muta...
Abstract 1453: Transcriptoma analyses in triple-negative breast cancer with BRCA1 germline mutation
Abstract 1453: Transcriptoma analyses in triple-negative breast cancer with BRCA1 germline mutation
Abstract Triple-negative breast cancer (TNBC), characterized by lack of expression of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal grow...
Identification of shared neoantigens in BRCA1-related breast cancer
Identification of shared neoantigens in BRCA1-related breast cancer
Personalized neoantigen-based cancer vaccine has been shown to be safe and immunogenic in cancer patients; however, the manufacturing process can be costly and brings about delay i...
Estrogen Rececptor (ER)-Positive Breast Cancers in BRCA1 Mutation Carriers: Mutation-Related or Sporadic?
Estrogen Rececptor (ER)-Positive Breast Cancers in BRCA1 Mutation Carriers: Mutation-Related or Sporadic?
Abstract Background: Most invasive breast cancers (IBC) in BRCA1 mutation carriers are ER negative (-) and have a basal-like phenotype by expression array analysis. ...
BRCA1/2 Serves as a Biomarker for Poor Prognosis in Breast Carcinoma
BRCA1/2 Serves as a Biomarker for Poor Prognosis in Breast Carcinoma
BRCA1/2 are breast cancer susceptibility genes that are involved in DNA repair and transcriptional control. They are dysregulated in breast cancer, making them attractive therapeut...
Pregnancy Hormone Mediated Tumorigenesis in BRCA1 Defective Breast Cancers
Pregnancy Hormone Mediated Tumorigenesis in BRCA1 Defective Breast Cancers
Background and Objective BRCA1 mutations predispose to breast and ovarian cancers, the exact reason for the tissue specificity is unknown. The role of hormonal ...

Back to Top